This post was originally published on this site
Closing yesterday’s session at $60.15, the stock is trading 13.8% below the 52-week high of $69.75.
Though the stock’s price has dipped 13.1% over the past month, its impressive growth potential, significant clinical and regulatory milestones, and strategic collaborations with biopharmaceutical companies, including Pfizer , Inc. (NYSE:PFE), Otsuka Pharmaceutical Co., Ltd., and Bolt Biotherapeutics, Inc., are expected to boost its performance in the coming months. Furthermore, BMY’s robust product portfolio should help it achieve sustained growth.
